These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33309946)

  • 41. Simultaneous sequential monitoring of efficacy and safety led to masking of effects.
    van Eekelen R; de Hoop E; van der Tweel I
    J Clin Epidemiol; 2016 Aug; 76():155-65. PubMed ID: 26944293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Bayesian sequential design using alpha spending function to control type I error.
    Zhu H; Yu Q
    Stat Methods Med Res; 2017 Oct; 26(5):2184-2196. PubMed ID: 26187736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multi-arm group sequential designs with a simultaneous stopping rule.
    Urach S; Posch M
    Stat Med; 2016 Dec; 35(30):5536-5550. PubMed ID: 27550822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved group sequential Holm procedures for testing multiple correlated hypotheses over time.
    Öhrn F; Niewczas J; Burman CF
    J Biopharm Stat; 2022 Mar; 32(2):230-246. PubMed ID: 34686107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni-based closed tests.
    Strassburger K; Bretz F
    Stat Med; 2008 Oct; 27(24):4914-27. PubMed ID: 18618415
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.
    Sugimoto T; Sozu T; Hamasaki T; Evans SR
    Biostatistics; 2013 Jul; 14(3):409-21. PubMed ID: 23307913
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reducing overestimation of the treatment effect by interim analysis when designing clinical trials.
    Shimura M
    J Clin Pharm Ther; 2019 Apr; 44(2):243-248. PubMed ID: 30414384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonparametric sequential monitoring of longitudinal trials.
    Bogowicz P; Gombay E; Heo G
    Stat Med; 2010 Oct; 29(24):2469-79. PubMed ID: 20690108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints.
    Cortés Martínez J; Geskus RB; Kim K; Melis GG
    BMC Med Res Methodol; 2021 May; 21(1):99. PubMed ID: 33957892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Weighted multiple hypothesis testing procedures.
    Kang G; Ye K; Liu N; Allison DB; Gao G
    Stat Appl Genet Mol Biol; 2009; 8(1):Article23. PubMed ID: 19409067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints.
    Sinha AK; Moye L; Piller LB; Yamal JM; Barcenas CH; Lin J; Davis BR
    Stat Med; 2019 Sep; 38(21):3985-3996. PubMed ID: 31184783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.
    Asakura K; Hamasaki T; Evans SR
    Biom J; 2017 Jul; 59(4):703-731. PubMed ID: 27757980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A power study of a sequential method of p-value adjustment for correlated continuous endpoints.
    Arani RB; Chen JJ
    J Biopharm Stat; 1998 Nov; 8(4):585-98. PubMed ID: 9855036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analyses of group sequential clinical trials.
    Koepcke W
    Control Clin Trials; 1989 Dec; 10(4 Suppl):222S-230S. PubMed ID: 2691210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials.
    Flight L; Julious S; Brennan A; Todd S
    Med Decis Making; 2022 May; 42(4):461-473. PubMed ID: 34859693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Selection of hypothesis weights and ordering when testing multiple hypotheses in clinical trials.
    Wiens BL; Dmitrienko A; Marchenko O
    J Biopharm Stat; 2013; 23(6):1403-19. PubMed ID: 24138439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. On the design and analysis of randomized clinical trials with multiple endpoints.
    Tang DI; Geller NL; Pocock SJ
    Biometrics; 1993 Mar; 49(1):23-30. PubMed ID: 8513104
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reducing unnecessary measurements in clinical trials with multiple primary endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2016; 26(4):631-43. PubMed ID: 26098617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.